Attn! Always use a VPN when RSSing!
Your IP adress is . Country:
Your ISP blocks content and issues fines based on your location. Hide your IP address with a VPN!
Bonus: No download restrictions, fines or annoying ads with any VPN Purchased!
Are you the publisher? Claim or contact us about this channel


Embed this content in your HTML

Search

Report adult content:

click to rate:

Account: (login)

More Channels


Channel Catalog


Channel Description:

Active Clearance Technology

older | 1 | 2 | (Page 3)

    0 0

    Anaheim, CA – April 18, 2017—ClearFlow Inc., a medical device company based in Anaheim, California, has received the prestigious 2017 Global Frost & Sullivan Award for New Product Innovation. The award was presented to ClearFlow for its development of the PleuraFlow® Active Clearance Technology® (ACT®) System, which has been clinically shown to reduce the occurrence of complications after cardiac surgery. Evidence suggests that chest tubes which are used for drainage after cardiac surgery have a high failure rate due to clogging. If the extra blood isn’t removed from inside the chest cavity after surgery, patients may require additional procedures which are known as Retained Blood Syndrome (RBS). Multiple studies have shown

    The post Frost & Sullivan New Product Innovation Award for PleuraFlow Technology appeared first on ClearFlow.


    0 0

    Anaheim, CA – June 20, 2017 — ClearFlow, Inc., a medical device company based in Anaheim, California, announced today that the United States Food & Drug Administration (FDA) has granted 510[k] clearance for the company’s proprietary FlowGlide™ Active Clearance Technology® System. The FlowGlide™ System is the next generation of ClearFlow’s Active Clearance Technology that prevents or reduces chest drains from occluding with clot, which can lead to retained blood around the heart and lungs. The composite of drainage-related complications that are detrimental to outcomes after cardiothoracic surgery and that may require early or late intervention to remediate is known as Retained Blood Syndrome (RBS). These clinical complications have significant economic

    The post FlowGlide Technology for Cardiac Surgery Patients, Cleared by FDA appeared first on ClearFlow.


    0 0

    Anaheim, CA – July 19, 2017 — ClearFlow, Inc., a medical device company based in Anaheim, California, has announced a full market release for the 20Fr SEDL version of the PleuraFlow® Active Clearance Technology® System for the treatment of pediatric cardiothoracic surgery patients. The SEDL refers to the “shorter effective drainage length”, which facilitates placement of the PleuraFlow chest tube in the smaller chests of pediatric patients. ClearFlow received clearance from the United States Food & Drug Administration (FDA) as well as the CE mark last year for expanded Indications for Use with the company’s patented technology and developed a new model of the PleuraFlow product for the pediatric market.

    The post PleuraFlow System available for Pediatric Cardiothoracic Surgery appeared first on ClearFlow.


    0 0

    Reduction of Hospital Complications and Resource Utilization after Heart Surgery Demonstrated with Use of the PleuraFlow® ACT® System. New York City, NY – August 21, 2017 — ClearFlow, Inc., a medical device company based in Anaheim, California, announced today that positive clinical trial results were presented at the International Coronary Congress (ICC) 2017 annual meeting on August 18th, 2017 in New York City, NY. The findings were presented by the study principal investigator, Dr. Yvon Baribeau, of Catholic Medical Center in Manchester, New Hampshire, in a presentation titled “Active Clearance of Chest Drains Reduces Retained Blood and ICU Resources after Off-Pump Coronary Artery Bypass Surgery”. This data stems from a

    The post ClearFlow, Inc. Announces Positive US Clinical Trial Results appeared first on ClearFlow.


    0 0

    –Study Supports Previously Published Data on Reduction of Postoperative Atrial Fibrillation After Heart Surgery Among Patients Treated with PleuraFlow Active Clearance Technology– Anaheim, CA – September 27, 2017—ClearFlow Inc., a medical device company based in Anaheim, California, has announced the publication of significantly positive results in a study evaluating the company’s PleuraFlow® Active Clearance Technology® System. Data from a peer-reviewed clinical study indicating a marked reduction in Postoperative Atrial Fibrillation (POAF) among patients with active clearance of chest tubes after heart surgery was published in the August edition of the Journal of Thoracic and Cardiovascular Surgery. The study is titled “Examining the impact of active clearance of chest drainage catheters

    The post Peer Reviewed Study Reveals Benefits of ClearFlow’s PleuraFlow ACT System appeared first on ClearFlow.


    0 0

    –ClearFlow spokespeople cite review article as latest piece of mounting evidence pertaining to urgent need for managing retained blood after surgery– Anaheim, CA – February 1, 2018—ClearFlow Inc., a medical device company based in Anaheim, California, has announced that the cover of the January, 2018 issue of The Annals of Thoracic Surgery features a review article that elucidates the biological mechanisms by which retained shed mediastinal blood can trigger postoperative atrial fibrillation (POAF) in susceptible individuals as well as how this could represent a new target for prevention of POAF. The article can be viewed online here: http://www.annalsthoracicsurgery.org/article/S0003-4975(17)31095-0/fulltext The article’s author group is comprised of key opinion leaders on the

    The post Studies Recognizing the Importance of Limiting Retained Blood to Prevent Postoperative Atrial Fibrillation Featured on January Cover of Annals of Thoracic Surgery appeared first on ClearFlow.


    0 0

      San Diego, California – May 2, 2018 – ClearFlow Inc. has announced that an international society of leading heart surgeons known as ERAS® Cardiac Surgery presented evidenced-based expert consensus statements at the 98th annual meeting of the American Association for Thoracic Surgeons on April 28, 2018. Amongst key recommendations to promote enhanced patient outcomes after cardiac surgery is the use of Active Clearance techniques to maintain chest tube patency.  The PleuraFlow® ACT® System is the only FDA cleared device with the indication to prevent or minimize retained blood in patients recovering from heart surgery. The PleuraFlow ACT System is indicated for use during cardiothoracic surgical procedures and chest trauma.

    The post ClearFlow Reports: ERAS Cardiac Surgery Recommends Active Tube Clearance Methodology in Consensus Statement Presented at the 98th Annual Meeting of The American Association for Thoracic Surgeons appeared first on ClearFlow.


    0 0

    ClearFlow Announces Additional Positive US Clinical Trial Results at the 2018 NTI Critical Care Exposition Reduction of Hospital Complications and Resource Utilization after Heart Surgery Demonstrated with Use of the PleuraFlow® ACT® System.  Boston, MA – May 29th, 2018 — ClearFlow, Inc., a medical device company based in Anaheim, California, has announced that positive clinical trial results were presented at the National Teaching Institute (NTI) & Critical Care Exposition 2018 annual meeting on May 23rd, 2018 in Boston, MA.  The findings were presented by the study principal investigator, Dr. Yvon Baribeau, of Catholic Medical Center in Manchester, New Hampshire, in a presentation titled “Active Clearance of Chest Drains Reduces Pleural

    The post ClearFlow Announces Additional Positive US Clinical Trial Results at the 2018 NTI Critical Care Exposition appeared first on ClearFlow.


    0 0

    ClearFlow Awarded Chest Drainage Products Agreement with Premier Anaheim, CA – August 21, 2018— ClearFlow, Inc., a medical device company based in Anaheim, California, announced today that it has been awarded a group purchasing agreement for the Chest Drainage Products category with Premier. Effective July 15th 2018, the new agreement allows Premier members, at their discretion, to take advantage of special pricing and terms pre-negotiated by Premier for: –PleuraFlow Active Clearance Technology (ACT) System; –PleuraFlow Active Clearance Technology (ACT) System with FlowGlide “ClearFlow is proud to now be able to bring its Active Clearance Technology devices to Premier members under these new arrangements with one of the country’s leading GPOs,”

    The post ClearFlow Awarded Chest Drainage Products Agreement with Premier appeared first on ClearFlow.


    0 0

    ERAS Cardiac Surgery Featured at Dedicated Session at European Association for Cardio-Thoracic Surgery in Milan   Springfield, MA — October 24, 2018 — The ERAS Cardiac Surgery Society presented its recent consensus statement at the 32nd European Association for Cardio-Thoracic Surgery (EACTS) Annual Meeting in Milan, Italy, last week as part of an educational session.   This dedicated ERAS Cardiac Surgery session was held during EACTS, the world’s largest cardiothoracic surgery focused professional conference with international speakers across all subspecialties.   ERAS Cardiac Surgery is a patient safety organization with the mission to facilitate optimization of perioperative care of cardiac surgical patients through collaborative discovery, analysis, expert consensus, and dissemination of best

    The post ERAS Cardiac Surgery Featured at Dedicated Session at European Association for Cardio-Thoracic Surgery in Milan appeared first on ClearFlow.


older | 1 | 2 | (Page 3)